Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071142357> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2071142357 endingPage "S207" @default.
- W2071142357 startingPage "S207" @default.
- W2071142357 abstract "This study aimed to evaluate the feasibility and efficacy of docetaxel and cisplatin neoadjuvant chemotherapy followed by intensity modulated radiation therapy (IMRT) with concurrent cisplatin in patients with locally advanced nasopharyngeal carcinoma. From June 2008 until October 2010, 46 patients diagnosed with stage III to IVB nasopharyngeal carcinoma were recruited in this phase II trial. All patients received 2 cycles of docetaxel (75 mg/m2) plus cisplatin (75 mg/m2) on day 1 every 3 weeks, followed by intensity-modulated radiation therapy (72 Gy/33F/6.5-7w) with concurrent cisplatin (75 mg/m2) every 3 weeks. Among these patients, 45 patients completed both neoadjuvant chemotherapy and concurrent chemoradiation therapy. The objective complete response rates and partial response rates were 28.3%, 56.5% after neoadjuvant chemotherapy and 91.3%, 8.7% after concurrent chemoradiation therapy, respectively. The median follow-up time was 26 months (range, 12-39 months). One patients experienced regional recurrence and four patients developed distant metastasis. The 3-year overall survival rate and progression-free survival rate were 94.1% and 72.7%, respectively. Neutropenia (37.0%) and vomiting (28.3%) were the most common acute grades 3-4 toxicities during neoadjuvant chemotherapy while mucositis (30.4%), xerostomia (30.4%), skin (21.7%) were the most common grades 3-4 toxicities during concurrent chemoradiation therapy. Xerostomia (73.9%), dysphagia (56.5%), hear loss (30.4%) and skin (21.7%) were the common late grade 1-2 radiation toxicities. There were no grades 3-4 late radiation toxicity. Neoadjuvant docetaxel-cisplatin followed by IMRT with concurrent cisplatin was well feasible and effective in treating local advanced nasopharyngeal carcinoma. Further investigation to test this strategy is warranted." @default.
- W2071142357 created "2016-06-24" @default.
- W2071142357 creator A5017179656 @default.
- W2071142357 creator A5025939565 @default.
- W2071142357 creator A5063310582 @default.
- W2071142357 creator A5073254297 @default.
- W2071142357 creator A5074004084 @default.
- W2071142357 creator A5089995875 @default.
- W2071142357 date "2012-11-01" @default.
- W2071142357 modified "2023-09-28" @default.
- W2071142357 title "Phase II Trial of Docetaxel and Cisplatin Neoadjuvant Chemotherapy Followed by Intensity Modulated Radiation Therapy With Concurrent Cisplatin in Advanced Nasopharyngeal Carcinoma" @default.
- W2071142357 doi "https://doi.org/10.1016/j.ijrobp.2012.07.538" @default.
- W2071142357 hasPublicationYear "2012" @default.
- W2071142357 type Work @default.
- W2071142357 sameAs 2071142357 @default.
- W2071142357 citedByCount "1" @default.
- W2071142357 countsByYear W20711423572014 @default.
- W2071142357 crossrefType "journal-article" @default.
- W2071142357 hasAuthorship W2071142357A5017179656 @default.
- W2071142357 hasAuthorship W2071142357A5025939565 @default.
- W2071142357 hasAuthorship W2071142357A5063310582 @default.
- W2071142357 hasAuthorship W2071142357A5073254297 @default.
- W2071142357 hasAuthorship W2071142357A5074004084 @default.
- W2071142357 hasAuthorship W2071142357A5089995875 @default.
- W2071142357 hasConcept C121608353 @default.
- W2071142357 hasConcept C126322002 @default.
- W2071142357 hasConcept C143998085 @default.
- W2071142357 hasConcept C2776694085 @default.
- W2071142357 hasConcept C2777063308 @default.
- W2071142357 hasConcept C2778239845 @default.
- W2071142357 hasConcept C2778292576 @default.
- W2071142357 hasConcept C2778496288 @default.
- W2071142357 hasConcept C2778997737 @default.
- W2071142357 hasConcept C2781190966 @default.
- W2071142357 hasConcept C509974204 @default.
- W2071142357 hasConcept C530470458 @default.
- W2071142357 hasConcept C71924100 @default.
- W2071142357 hasConceptScore W2071142357C121608353 @default.
- W2071142357 hasConceptScore W2071142357C126322002 @default.
- W2071142357 hasConceptScore W2071142357C143998085 @default.
- W2071142357 hasConceptScore W2071142357C2776694085 @default.
- W2071142357 hasConceptScore W2071142357C2777063308 @default.
- W2071142357 hasConceptScore W2071142357C2778239845 @default.
- W2071142357 hasConceptScore W2071142357C2778292576 @default.
- W2071142357 hasConceptScore W2071142357C2778496288 @default.
- W2071142357 hasConceptScore W2071142357C2778997737 @default.
- W2071142357 hasConceptScore W2071142357C2781190966 @default.
- W2071142357 hasConceptScore W2071142357C509974204 @default.
- W2071142357 hasConceptScore W2071142357C530470458 @default.
- W2071142357 hasConceptScore W2071142357C71924100 @default.
- W2071142357 hasIssue "3" @default.
- W2071142357 hasLocation W20711423571 @default.
- W2071142357 hasOpenAccess W2071142357 @default.
- W2071142357 hasPrimaryLocation W20711423571 @default.
- W2071142357 hasRelatedWork W2029866643 @default.
- W2071142357 hasRelatedWork W2071142357 @default.
- W2071142357 hasRelatedWork W2356838307 @default.
- W2071142357 hasRelatedWork W2359686091 @default.
- W2071142357 hasRelatedWork W2377959084 @default.
- W2071142357 hasRelatedWork W2413359889 @default.
- W2071142357 hasRelatedWork W2591479921 @default.
- W2071142357 hasRelatedWork W3028665314 @default.
- W2071142357 hasRelatedWork W3030223433 @default.
- W2071142357 hasRelatedWork W3094360059 @default.
- W2071142357 hasVolume "84" @default.
- W2071142357 isParatext "false" @default.
- W2071142357 isRetracted "false" @default.
- W2071142357 magId "2071142357" @default.
- W2071142357 workType "article" @default.